Back to top
more

Merit Medical Systems (MMSI)

(Delayed Data from NSDQ)

$85.65 USD

85.65
493,550

+2.10 (2.51%)

Updated Aug 7, 2025 04:00 PM ET

Pre-Market: $85.65 0.00 (0.00%) 8:44 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 244)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why You Should Retain DaVita (DVA) Stock for Now

by Zacks Equity Research

Investors remain optimistic about DaVita (DVA) due to the strength of its DaVita Kidney Care.

Zacks Equity Research

Bio-Rad (BIO) Faces Macroeconomic Headwinds, Rising Expenses

by Zacks Equity Research

Bio-Rad's (BIO) process chromatography business witnesses a slowdown in the quarter due to tough comparisons and some softness in the bioprocessing market.

Zacks Equity Research

Veeva Systems (VEEV) Extends Tie-Up With Lotus Clinical

by Zacks Equity Research

Veeva Systems (VEEV) expands its partnership with Lotus Clinical to accelerate clinical trials.

Zacks Equity Research

Here's Why You Should Invest in Haemonetics (HAE) Right Now

by Zacks Equity Research

Investors are optimistic about Haemonetics (HAE), led by the impressive performance of Plasma and Hospital businesses.

Zacks Equity Research

Boston Scientific (BSX) Rises 26.4%: Will the Rally Continue?

by Zacks Equity Research

Boston Scientific (BSX) gains from strong improvement in organic sales, indicating a solid rebound in the legacy business.

Zacks Equity Research

Stryker's (SYK) Q Guidance Successful in First Surgery

by Zacks Equity Research

Stryker (SYK) successfully completes first surgical case using its Q Guidance system with Cranial Guidance software. An Early Product Surveillance is underway for the combined technology.

Zacks Equity Research

Catalent (CTLT) Expands Its Facility Capabilities in Shiga

by Zacks Equity Research

Catalent's (CTLT) latest capability expansion is expected to boost its business in the global clinical trials space in its Clinical Supply Services network.

Zacks Equity Research

Abbott (ABT) Reports Upbeat Cardiomems Sensor Study Result

by Zacks Equity Research

Abbott's (ABT) MONITOR-HF is the third randomized, controlled trial that will provide significant health benefits to indicated heart failure patients.

Zacks Equity Research

Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio

by Zacks Equity Research

AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Zacks Equity Research

Here's Why Investors Should Retain STERIS (STE) Stock for Now

by Zacks Equity Research

Investors are optimistic about STERIS (STE) on strong segmental growth.

Zacks Equity Research

Why Is Merit Medical (MMSI) Down 1% Since Last Earnings Report?

by Zacks Equity Research

Merit Medical (MMSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Veeva Systems (VEEV) Offerings Adopted by Minaris Regenerative

by Zacks Equity Research

Veeva Systems' (VEEV) Vault Quality Suite applications are expected to aid the CDMO to modernize its operations and streamline its quality processes globally.

Zacks Equity Research

Medtronic (MDT) to Expand Diabetes Care With New Buyout

by Zacks Equity Research

Medtronic's (MDT) latest acquisition will increase its capacity to assist more individuals with diabetes worldwide within a single, seamless Medtronic support ecosystem.

Zacks Equity Research

Here's Why You Should Retain Stryker (SYK) Stock for Now

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on the stock.

Zacks Equity Research

Here's Why You Should Retain CVS Health (CVS) Stock for Now

by Zacks Equity Research

Investors are optimistic about CVS Health (CVS) on continued growth across the entire range of insured and self-insured medical, pharmacy, dental and behavioral health products and services.

Zacks Equity Research

Medtronic (MDT) Q4 Earnings Beat Estimates, Margins Down

by Zacks Equity Research

Strong growth in the Cardiovascular, Medical Surgical, and Neuroscience portfolios, and in Diabetes markets drove Medtronic (MDT) Q4 revenues.

Zacks Equity Research

Masimo's (MASI) Platform Expansion to Boost Patient Monitoring

by Zacks Equity Research

Masimo's (MASI) latest expansion to its HEOS platform will likely revolutionize health and wellness tracking by allowing connected care as consumers become tetherless and smartphone-less.

Zacks Equity Research

Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Stock

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.

Zacks Equity Research

3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about DexCom (DXCM), owing to its strong product portfolio.

Zacks Equity Research

Thermo Fisher (TMO) Expands Manufacturing Facility in APAC

by Zacks Equity Research

Thermo Fisher (TMO) latest expansion will enable it to better assist clients in accelerating their research, development and marketing of medications and vaccines in the Asia-Pacific region.

Zacks Equity Research

Accuray (ARAY) Hits 52-Week High: What's Aiding the Stock?

by Zacks Equity Research

Investors are optimistic about Accuray's (ARAY) solid product portfolio.

Zacks Equity Research

Veeva Systems' (VEEV) New Tie-Up to Improve Clinical Trials

by Zacks Equity Research

Veeva Systems' (VEEV) latest collaboration is expected to advance the patient experience in clinical trials.

Zacks Equity Research

ShockWave Medical (SWAV) Hits 52-Week High: Will it Continue?

by Zacks Equity Research

ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.

Zacks Equity Research

Avantor's (AVTR) New Tie-Up to Improve Lab Inventory Management

by Zacks Equity Research

Avantor's (AVTR) latest partnership is expected to significantly optimize labs' inventory management and the overall workflow.

Zacks Equity Research

Intuitive Surgical (ISRG) Hits 52-Week High: What's Driving It?

by Zacks Equity Research

Intuitive Surgical (ISRG) outperforms the industry and the S&P 500 Index due to its strength in robotics.